Liquid biopsy in head and neck cancer patients: blood, saliva, or both ?

Ethics declaration

The present work was carried out at the IRCCS Regina Elena National Cancer Institute. Authorization from the Institutional Ethic Review Board (RS868/16) was obtained, and written informed consent was collected from the human subject involved in this analysis.

Acknowledgments

This work was supported Ministry of Health PNRR (funding issued according to “Missione 6/componente 2/Investimento: 2.1- Rafforzamento e potenziamento della ricerca biomedica del SSN”, funding by NextGenerationEU/H53C22001150001 to BG). PNRR-POC-2022-12376580: “Analyses of HPV and host body fluid biomarkers as non-invasive strategy for detection of head and neck cancer relapse”.

Author contributions

Valentina De Pascale (Data curation, Formal analysis, Investigation, Methodology, Writing—original draft), Federica Ganci (Investigation, Methodology, Writing—review & editing), Fabrizio Leone (Methodology), Valentina Manciocco (Investigation), Flaminia Campo (Investigation), Anastasia Mercurio (Investigation), Alina Catalina Palcau (Methodology), Claudio Moretti (Investigation), Frauke Goeman (Investigation), Sara Donzelli (Writing—review & editing), Giulia Orlandi (Software), Federica Orrù (Investigation), Renato Covello (Investigation, Methodology), Paola Muti (Writing—review & editing), Sabrina Strano (Writing—review & editing), Antonello Vidiri (Investigation, Software), Raul Pellini (Investigation), and Giovanni Blandino (Conceptualization, Project administration, Resources, Supervision, Writing—review & editing).

Conflict of interest

None declared. However, it needs to be stated that both the custom mutational panel including the full coding sequence of TP53, CDKN2A, and FAT1 and the 4-microRNAs signature have been patented by G.B. and F.G., (#102020000017896), and by G.B., F.G., V.M., and R.P. (#102020000019024), respectively.

References

[1] Pisani P, Airoldi M, Allais A et al. Metastatic disease in head & neck oncology. Acta Otorhinolaryngol Ital 2020;40:S1-86.

[2] Markou A, Tzanikou E, Lianidou E. The potential of liquid biopsy in the management of cancer patients. Semin Cancer Biol 2022;84:69-79. https://doi.org/10.1016/j.semcancer.2022.03.013.

[3] Malapelle U, Pisapia P, Pepe F et al. The evolving role of liquid biopsy in lung cancer. Lung Cancer 2022;172:53-64. https://doi.org/10.1016/j.lungcan.2022.08.004.

[4] Pantel K, Alix-Panabières C. Minimal residual disease as a target for liquid biopsy in patients with solid tumours. Nat Rev Clin Oncol 2025;22:65-77. https://doi.org/10.1038/s41571-024-00967-y.

[5] Zhou H, Zhu L, Song J et al. Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer. Mol Cancer 2022;21:86. https://doi.org/10.1186/s12943-022-01556-2.

[6] Wang Y, Springer S, Mulvey CL et al. Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Sci Transl Med 2015;7:293ra104. https://doi.org/10.1126/scitranslmed.aaa8507.

[7] Castro-Giner F, Gkountela S, Donato C et al. Cancer Diagnosis Using a Liquid Biopsy: Challenges and Expectations. Diagnostics 2018;8:31. https://doi.org/10.3390/diagnostics8020031.

[8] Shanmugam A, Hariharan AK, Hasina R et al. Ultrasensitive detection of tumor-specific mutations in saliva of patients with oral cavity squamous cell carcinoma. Cancer 2021;127:1576-89. https://doi.org/10.1002/cncr.33393.

[9] Ganci F, Allegretti M, Frascolla C et al. Correction: Combined TP53 status in tumor-free resection margins and circulating microRNA profiling predicts the risk of locoregional recurrence in head and neck cancer. Biomark Res 2024;12:37. https://doi.org/10.1186/s40364-024-00582-0.